The Journal of Informed Pharmacotherapy 2002;11:411.
Trana Hussaini B.Sc. (Pharm), Nilufar Partovi, B.Sc. (Pharm), Pharm.D., FCSHP, RJ Shapiro, MD, FRCP
Pharmaceutical Sciences Clinical Service Unit, Vancouver General Hospital , Vancouver Hospital and Health Sciences Center, Vancouver, British Columbia, Canada
Canadian Society of Hospital Pharmacists (British Columbia Branch) Residency Research Presentation Night, Vancouver, British Columbia, Canada. May 8, 2002.
Cardiovascular disease (CVD) is the cause of death in almost half of renal transplant recipients with functioning grafts. Cardiac risk factors in general population, such as dyslipidemia are also predictive in transplant patients. The primary objectives of this study were to characterize and stratify cardiac risk factors in renal transplant patients at our outpatient clinic and to develop and implement a dyslipidemia-management protocol in this population.
A major Canadian tertiary adult acute care teaching hospital.
Medical charts for a total of 98 patients transplanted between Jan 1998 to Oct 2001 were reviewed and cardiac risk factors using Framingham scoring system were determined. A dyslipidemia management protocol was developed based on NCEP Guidelines and a copy of this protocol was inserted in medical records of 42 patients, stating their calculated 10-year cardiac risk percentage and a dyslipidemia treatment option based on NCEP Guidelines.
A significant number of transplant recipients were at intermediate to high risk for developing CVD. Majority of patients had elevated lipids and only a small fraction were receiving antilipid therapy. Our protocol was not effectively utilized as indicated by the small number of patients receiving antilipid therapy.
Considering high prevalence of CVD in transplant patients, aggressive intervention with lipid lowering therapy seems warranted.
Copyright © 2002 by the Journal of Informed Pharmacotherapy. All rights reserved.